Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers-论文-万方医学网

首页> > Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers

导出原文传递

翻译打印收藏纠错

第一作者： Li, Xiaojiao

作者： Li, Xiaojiao ^[1] ; Li, Bing ^[2] ; Wang, Meng ^[3] ; Fang, Min ^[4] ; Lou, Jinfeng ; Liu, Jingrui ; Chen, Hong ; Ding, Yanhua

作者单位： Prolynx IncUCSF University of California System University of California San Francisco Pharmaceut ^[1] Qyuns Therapeut Co Ltd ^[2] Qyuns Therapeut Co LtdFirst Hosp Jilin Univ Jilin University Phase 1 Clin Trail Ctr ^[3] Qyuns Therapeut Co LtdFirst Hosp Jilin Univ Jilin University Phase 1 Clin Trail Ctr First Hosp ^[4]

关键词 PHASE-I ANIFROLUMAB

发布时间 2024-04-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers

相似文献

同项目论文

相关期刊

检索历史 清除

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers

相似文献

同项目论文

相关期刊

检索历史清除